New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
06:06 EDTIMUCImmunoCellular granted orphan drug designation for ICT-107 by EMA
ImmunoCellular Therapeutics announced that the European Medicines Agency, or EMA, has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular has previously received orphan designation for ICT-107 in glioblastoma in the US.
News For IMUC From The Last 14 Days
Check below for free stories on IMUC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
06:05 EDTIMUCImmunoCellular receives positive regulatory feedback on ICT-107
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use